effect of pegylated recombinant human leptin (PEG-OB) on weight loss and inflammatory status in obese subjects

OBJECTIVE: To investigate whether weekly subcutaneous administration of 60 mg of long-acting pegylated human leptin (PEG-OB) for 8 weeks was able to influence weight loss, metabolic profile and inflammatory status of obese subjects on a mildly hypoenergetic diet (deficit: 3.2 MJ/day). DESIGN: A pros...

Full description

Saved in:
Bibliographic Details
Published in:International Journal of Obesity 2002-04, Vol.26 (4), p.504-509
Main Authors: Hukshorn, C.J, Dielen, F.M.H. van, Buurman, W.A, Westerterp-Plantenga, M.S, Campfield, L.A, Saris, W.H.M
Format: Article
Language:English
Subjects:
Analysis. Health state
Biological and medical sciences
Body mass index
C-reactive protein
Cytokines
Diet
Drug dosages
Epidemiology
General aspects
humans
leptin
Lipids
low calorie diet
Medical sciences
men
Metabolic diseases
Metabolism
Nutrition research
Obesity
Proteins
Public health. Hygiene
Public health. Hygiene-occupational medicine
subcutaneous injection
Substance abuse treatment
Tumor necrosis factor-TNF
tumor necrosis factors
Weight control
weight loss
women
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c383t-d7547f5e849b513c5292b891c5610645816cf77ae7ad071e4f5c74be51a316ce3
cites cdi_FETCH-LOGICAL-c383t-d7547f5e849b513c5292b891c5610645816cf77ae7ad071e4f5c74be51a316ce3
container_end_page 509
container_issue 4
container_start_page 504
container_title International Journal of Obesity
container_volume 26
creator Hukshorn, C.J
Dielen, F.M.H. van
Buurman, W.A
Westerterp-Plantenga, M.S
Campfield, L.A
Saris, W.H.M
description OBJECTIVE: To investigate whether weekly subcutaneous administration of 60 mg of long-acting pegylated human leptin (PEG-OB) for 8 weeks was able to influence weight loss, metabolic profile and inflammatory status of obese subjects on a mildly hypoenergetic diet (deficit: 3.2 MJ/day). DESIGN: A prospective, randomized, double-blind and placebo-controlled single-center trial. SUBJECTS: Twenty-eight healthy, obese subjects (16 women, 12 men; age 22-65 y; body mass index 27.7-38.7 kg/m2). MEASUREMENTS: Bodyweight, metabolic profile (including lipids), C-reactive protein (CRP) and soluble TNF α-receptor (sTNF-R) 55 and 75 levels. RESULTS: At the end of the study no significant differences in the delta or percentage weight loss between the placebo (n=14) and PEG-OB (n=14) groups was observed. Also the changes in metabolic profile, CRP, sTNF-R55 and R75 concentrations between the two groups after 8 weeks of treatment did not differ. CONCLUSION: Weekly injection of 60 mg PEG-OB did not lead to additional weight loss after 8 weeks of treatment. Furthermore, PEG-OB administration did not affect the changes in metabolic profile and the inflammatory status of obese subjects.
doi_str_mv 10.1038/sj.ijo.0801952
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_219293200</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1011889901</sourcerecordid><originalsourceid>FETCH-LOGICAL-c383t-d7547f5e849b513c5292b891c5610645816cf77ae7ad071e4f5c74be51a316ce3</originalsourceid><addsrcrecordid>eNpFkEFr3DAQhUVpoNu0114rCoX24M1Isizr2IQ0LQQSSHMWsna0sbGlrSRT9t9XZRd6Gpj53nvMI-QDgy0D0V_laTtOcQs9MC35K7Jhreoa2Wr1mmxAgGpAdvINeZvzBABSAt-QgN6jKzR6esD9cbYFdzShi8swBhsKfVkXG-iMhzIG-uXx9q55uP5KY6B_cNy_FDrHnKkNOzoGP9tlsSWmI83FljXXHY0DZqR5HaYak9-RC2_njO_P85I8f7_9dfOjuX-4-3nz7b5xohel2SnZKi-xb_UgmXCSaz70mjnZMeha2bPOeaUsKrsDxbD10ql2QMmsqCcUl-TTyfeQ4u8VczFTXFOokYYzzbXgABXaniCX6hMJvTmkcbHpaBiYf5WaPJlaqTlXWgWfz642Ozv7ZIMb83-VkJr3WlTu44nzNhq7T5V5fuLAZK1dia4D8RcxBICO</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>219293200</pqid></control><display><type>article</type><title>effect of pegylated recombinant human leptin (PEG-OB) on weight loss and inflammatory status in obese subjects</title><source>Nature</source><creator>Hukshorn, C.J ; Dielen, F.M.H. van ; Buurman, W.A ; Westerterp-Plantenga, M.S ; Campfield, L.A ; Saris, W.H.M</creator><creatorcontrib>Hukshorn, C.J ; Dielen, F.M.H. van ; Buurman, W.A ; Westerterp-Plantenga, M.S ; Campfield, L.A ; Saris, W.H.M</creatorcontrib><description>OBJECTIVE: To investigate whether weekly subcutaneous administration of 60 mg of long-acting pegylated human leptin (PEG-OB) for 8 weeks was able to influence weight loss, metabolic profile and inflammatory status of obese subjects on a mildly hypoenergetic diet (deficit: 3.2 MJ/day). DESIGN: A prospective, randomized, double-blind and placebo-controlled single-center trial. SUBJECTS: Twenty-eight healthy, obese subjects (16 women, 12 men; age 22-65 y; body mass index 27.7-38.7 kg/m2). MEASUREMENTS: Bodyweight, metabolic profile (including lipids), C-reactive protein (CRP) and soluble TNF α-receptor (sTNF-R) 55 and 75 levels. RESULTS: At the end of the study no significant differences in the delta or percentage weight loss between the placebo (n=14) and PEG-OB (n=14) groups was observed. Also the changes in metabolic profile, CRP, sTNF-R55 and R75 concentrations between the two groups after 8 weeks of treatment did not differ. CONCLUSION: Weekly injection of 60 mg PEG-OB did not lead to additional weight loss after 8 weeks of treatment. Furthermore, PEG-OB administration did not affect the changes in metabolic profile and the inflammatory status of obese subjects.</description><identifier>ISSN: 0307-0565</identifier><identifier>EISSN: 1476-5497</identifier><identifier>DOI: 10.1038/sj.ijo.0801952</identifier><identifier>CODEN: IJOBDP</identifier><language>eng</language><publisher>Basingstoke: Nature Publishing Group</publisher><subject>Analysis. Health state ; Biological and medical sciences ; Body mass index ; C-reactive protein ; Cytokines ; Diet ; Drug dosages ; Epidemiology ; General aspects ; humans ; leptin ; Lipids ; low calorie diet ; Medical sciences ; men ; Metabolic diseases ; Metabolism ; Nutrition research ; Obesity ; Proteins ; Public health. Hygiene ; Public health. Hygiene-occupational medicine ; subcutaneous injection ; Substance abuse treatment ; Tumor necrosis factor-TNF ; tumor necrosis factors ; Weight control ; weight loss ; women</subject><ispartof>International Journal of Obesity, 2002-04, Vol.26 (4), p.504-509</ispartof><rights>2002 INIST-CNRS</rights><rights>Copyright Nature Publishing Group Apr 2002</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c383t-d7547f5e849b513c5292b891c5610645816cf77ae7ad071e4f5c74be51a316ce3</citedby><cites>FETCH-LOGICAL-c383t-d7547f5e849b513c5292b891c5610645816cf77ae7ad071e4f5c74be51a316ce3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=13592893$$DView record in Pascal Francis$$Hfree_for_read</backlink></links><search><creatorcontrib>Hukshorn, C.J</creatorcontrib><creatorcontrib>Dielen, F.M.H. van</creatorcontrib><creatorcontrib>Buurman, W.A</creatorcontrib><creatorcontrib>Westerterp-Plantenga, M.S</creatorcontrib><creatorcontrib>Campfield, L.A</creatorcontrib><creatorcontrib>Saris, W.H.M</creatorcontrib><title>effect of pegylated recombinant human leptin (PEG-OB) on weight loss and inflammatory status in obese subjects</title><title>International Journal of Obesity</title><description>OBJECTIVE: To investigate whether weekly subcutaneous administration of 60 mg of long-acting pegylated human leptin (PEG-OB) for 8 weeks was able to influence weight loss, metabolic profile and inflammatory status of obese subjects on a mildly hypoenergetic diet (deficit: 3.2 MJ/day). DESIGN: A prospective, randomized, double-blind and placebo-controlled single-center trial. SUBJECTS: Twenty-eight healthy, obese subjects (16 women, 12 men; age 22-65 y; body mass index 27.7-38.7 kg/m2). MEASUREMENTS: Bodyweight, metabolic profile (including lipids), C-reactive protein (CRP) and soluble TNF α-receptor (sTNF-R) 55 and 75 levels. RESULTS: At the end of the study no significant differences in the delta or percentage weight loss between the placebo (n=14) and PEG-OB (n=14) groups was observed. Also the changes in metabolic profile, CRP, sTNF-R55 and R75 concentrations between the two groups after 8 weeks of treatment did not differ. CONCLUSION: Weekly injection of 60 mg PEG-OB did not lead to additional weight loss after 8 weeks of treatment. Furthermore, PEG-OB administration did not affect the changes in metabolic profile and the inflammatory status of obese subjects.</description><subject>Analysis. Health state</subject><subject>Biological and medical sciences</subject><subject>Body mass index</subject><subject>C-reactive protein</subject><subject>Cytokines</subject><subject>Diet</subject><subject>Drug dosages</subject><subject>Epidemiology</subject><subject>General aspects</subject><subject>humans</subject><subject>leptin</subject><subject>Lipids</subject><subject>low calorie diet</subject><subject>Medical sciences</subject><subject>men</subject><subject>Metabolic diseases</subject><subject>Metabolism</subject><subject>Nutrition research</subject><subject>Obesity</subject><subject>Proteins</subject><subject>Public health. Hygiene</subject><subject>Public health. Hygiene-occupational medicine</subject><subject>subcutaneous injection</subject><subject>Substance abuse treatment</subject><subject>Tumor necrosis factor-TNF</subject><subject>tumor necrosis factors</subject><subject>Weight control</subject><subject>weight loss</subject><subject>women</subject><issn>0307-0565</issn><issn>1476-5497</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><recordid>eNpFkEFr3DAQhUVpoNu0114rCoX24M1Isizr2IQ0LQQSSHMWsna0sbGlrSRT9t9XZRd6Gpj53nvMI-QDgy0D0V_laTtOcQs9MC35K7Jhreoa2Wr1mmxAgGpAdvINeZvzBABSAt-QgN6jKzR6esD9cbYFdzShi8swBhsKfVkXG-iMhzIG-uXx9q55uP5KY6B_cNy_FDrHnKkNOzoGP9tlsSWmI83FljXXHY0DZqR5HaYak9-RC2_njO_P85I8f7_9dfOjuX-4-3nz7b5xohel2SnZKi-xb_UgmXCSaz70mjnZMeha2bPOeaUsKrsDxbD10ql2QMmsqCcUl-TTyfeQ4u8VczFTXFOokYYzzbXgABXaniCX6hMJvTmkcbHpaBiYf5WaPJlaqTlXWgWfz642Ozv7ZIMb83-VkJr3WlTu44nzNhq7T5V5fuLAZK1dia4D8RcxBICO</recordid><startdate>20020401</startdate><enddate>20020401</enddate><creator>Hukshorn, C.J</creator><creator>Dielen, F.M.H. van</creator><creator>Buurman, W.A</creator><creator>Westerterp-Plantenga, M.S</creator><creator>Campfield, L.A</creator><creator>Saris, W.H.M</creator><general>Nature Publishing Group</general><general>Nature Publishing</general><scope>FBQ</scope><scope>IQODW</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T2</scope><scope>7TK</scope><scope>7TS</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PSYQQ</scope><scope>Q9U</scope></search><sort><creationdate>20020401</creationdate><title>effect of pegylated recombinant human leptin (PEG-OB) on weight loss and inflammatory status in obese subjects</title><author>Hukshorn, C.J ; Dielen, F.M.H. van ; Buurman, W.A ; Westerterp-Plantenga, M.S ; Campfield, L.A ; Saris, W.H.M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c383t-d7547f5e849b513c5292b891c5610645816cf77ae7ad071e4f5c74be51a316ce3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Analysis. Health state</topic><topic>Biological and medical sciences</topic><topic>Body mass index</topic><topic>C-reactive protein</topic><topic>Cytokines</topic><topic>Diet</topic><topic>Drug dosages</topic><topic>Epidemiology</topic><topic>General aspects</topic><topic>humans</topic><topic>leptin</topic><topic>Lipids</topic><topic>low calorie diet</topic><topic>Medical sciences</topic><topic>men</topic><topic>Metabolic diseases</topic><topic>Metabolism</topic><topic>Nutrition research</topic><topic>Obesity</topic><topic>Proteins</topic><topic>Public health. Hygiene</topic><topic>Public health. Hygiene-occupational medicine</topic><topic>subcutaneous injection</topic><topic>Substance abuse treatment</topic><topic>Tumor necrosis factor-TNF</topic><topic>tumor necrosis factors</topic><topic>Weight control</topic><topic>weight loss</topic><topic>women</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hukshorn, C.J</creatorcontrib><creatorcontrib>Dielen, F.M.H. van</creatorcontrib><creatorcontrib>Buurman, W.A</creatorcontrib><creatorcontrib>Westerterp-Plantenga, M.S</creatorcontrib><creatorcontrib>Campfield, L.A</creatorcontrib><creatorcontrib>Saris, W.H.M</creatorcontrib><collection>AGRIS</collection><collection>Pascal-Francis</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Neurosciences Abstracts</collection><collection>Physical Education Index</collection><collection>Agricultural Science Collection</collection><collection>ProQuest Health and Medical</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>Agricultural &amp; Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Agriculture Science Database</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><jtitle>International Journal of Obesity</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hukshorn, C.J</au><au>Dielen, F.M.H. van</au><au>Buurman, W.A</au><au>Westerterp-Plantenga, M.S</au><au>Campfield, L.A</au><au>Saris, W.H.M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>effect of pegylated recombinant human leptin (PEG-OB) on weight loss and inflammatory status in obese subjects</atitle><jtitle>International Journal of Obesity</jtitle><date>2002-04-01</date><risdate>2002</risdate><volume>26</volume><issue>4</issue><spage>504</spage><epage>509</epage><pages>504-509</pages><issn>0307-0565</issn><eissn>1476-5497</eissn><coden>IJOBDP</coden><abstract>OBJECTIVE: To investigate whether weekly subcutaneous administration of 60 mg of long-acting pegylated human leptin (PEG-OB) for 8 weeks was able to influence weight loss, metabolic profile and inflammatory status of obese subjects on a mildly hypoenergetic diet (deficit: 3.2 MJ/day). DESIGN: A prospective, randomized, double-blind and placebo-controlled single-center trial. SUBJECTS: Twenty-eight healthy, obese subjects (16 women, 12 men; age 22-65 y; body mass index 27.7-38.7 kg/m2). MEASUREMENTS: Bodyweight, metabolic profile (including lipids), C-reactive protein (CRP) and soluble TNF α-receptor (sTNF-R) 55 and 75 levels. RESULTS: At the end of the study no significant differences in the delta or percentage weight loss between the placebo (n=14) and PEG-OB (n=14) groups was observed. Also the changes in metabolic profile, CRP, sTNF-R55 and R75 concentrations between the two groups after 8 weeks of treatment did not differ. CONCLUSION: Weekly injection of 60 mg PEG-OB did not lead to additional weight loss after 8 weeks of treatment. Furthermore, PEG-OB administration did not affect the changes in metabolic profile and the inflammatory status of obese subjects.</abstract><cop>Basingstoke</cop><pub>Nature Publishing Group</pub><doi>10.1038/sj.ijo.0801952</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0307-0565
ispartof International Journal of Obesity, 2002-04, Vol.26 (4), p.504-509
issn 0307-0565
1476-5497
language eng
recordid cdi_proquest_journals_219293200
source Nature
subjects Analysis. Health state
Biological and medical sciences
Body mass index
C-reactive protein
Cytokines
Diet
Drug dosages
Epidemiology
General aspects
humans
leptin
Lipids
low calorie diet
Medical sciences
men
Metabolic diseases
Metabolism
Nutrition research
Obesity
Proteins
Public health. Hygiene
Public health. Hygiene-occupational medicine
subcutaneous injection
Substance abuse treatment
Tumor necrosis factor-TNF
tumor necrosis factors
Weight control
weight loss
women
title effect of pegylated recombinant human leptin (PEG-OB) on weight loss and inflammatory status in obese subjects
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T23%3A35%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=effect%20of%20pegylated%20recombinant%20human%20leptin%20(PEG-OB)%20on%20weight%20loss%20and%20inflammatory%20status%20in%20obese%20subjects&rft.jtitle=International%20Journal%20of%20Obesity&rft.au=Hukshorn,%20C.J&rft.date=2002-04-01&rft.volume=26&rft.issue=4&rft.spage=504&rft.epage=509&rft.pages=504-509&rft.issn=0307-0565&rft.eissn=1476-5497&rft.coden=IJOBDP&rft_id=info:doi/10.1038/sj.ijo.0801952&rft_dat=%3Cproquest_cross%3E1011889901%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c383t-d7547f5e849b513c5292b891c5610645816cf77ae7ad071e4f5c74be51a316ce3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=219293200&rft_id=info:pmid/&rfr_iscdi=true